MX8958A - Procedimiento para obtener un preparado liofilizado que contiene ifosfamida. - Google Patents

Procedimiento para obtener un preparado liofilizado que contiene ifosfamida.

Info

Publication number
MX8958A
MX8958A MX895887A MX895887A MX8958A MX 8958 A MX8958 A MX 8958A MX 895887 A MX895887 A MX 895887A MX 895887 A MX895887 A MX 895887A MX 8958 A MX8958 A MX 8958A
Authority
MX
Mexico
Prior art keywords
procedure
obtaining
lyophilized preparation
preparation containing
ifosfamide
Prior art date
Application number
MX895887A
Other languages
English (en)
Inventor
Dieter Sauerbier
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of MX8958A publication Critical patent/MX8958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Control Of El Displays (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX895887A 1986-10-31 1987-10-23 Procedimiento para obtener un preparado liofilizado que contiene ifosfamida. MX8958A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (1)

Publication Number Publication Date
MX8958A true MX8958A (es) 1993-12-01

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX895887A MX8958A (es) 1986-10-31 1987-10-23 Procedimiento para obtener un preparado liofilizado que contiene ifosfamida.

Country Status (25)

Country Link
EP (1) EP0265812B1 (es)
JP (1) JPS63159319A (es)
KR (1) KR900003491B1 (es)
AT (1) ATE55250T1 (es)
AU (1) AU598602B2 (es)
CA (1) CA1314231C (es)
DD (1) DD262582A5 (es)
DE (1) DE3764235D1 (es)
DK (1) DK169308B1 (es)
EG (1) EG18333A (es)
ES (1) ES2017982B3 (es)
FI (1) FI87140C (es)
GE (1) GEP19971025B (es)
GR (1) GR3000708T3 (es)
HU (1) HU197987B (es)
IL (1) IL84312A (es)
IN (1) IN168119B (es)
LV (1) LV10051B (es)
MX (1) MX8958A (es)
NO (1) NO873860L (es)
PT (1) PT86032B (es)
RU (1) RU1836079C (es)
UA (1) UA11075A (es)
YU (1) YU197387A (es)
ZA (1) ZA878183B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE65402T1 (de) * 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
JP2006508917A (ja) * 2002-09-05 2006-03-16 ブハラット セルムズ アンド ヴァクシンズ リミテッド メスナを有する、オキサザホスホリンの液体安定性組成物
DE60332385D1 (de) * 2002-12-02 2010-06-10 Bharat Serums & Vaccines Ltd Ifosfamid-zusammensetzungen zur parenteralen verabreichung und verfahren für ihre herstellung
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2412359A1 (en) * 2006-09-29 2012-02-01 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
WO2016087001A1 (en) * 2014-12-04 2016-06-09 Huawei Technologies Co., Ltd. Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
EP0265812B1 (de) 1990-08-08
KR900003491B1 (ko) 1990-05-21
YU197387A (en) 1988-12-31
DE3764235D1 (de) 1990-09-13
AU598602B2 (en) 1990-06-28
NO873860L (no) 1988-05-02
EP0265812A1 (de) 1988-05-04
GR3000708T3 (en) 1991-10-10
FI87140B (fi) 1992-08-31
GEP19971025B (en) 1997-04-06
FI874727A0 (fi) 1987-10-27
DK169308B1 (da) 1994-10-10
IL84312A (en) 1991-11-21
JPH0543684B2 (es) 1993-07-02
ZA878183B (en) 1988-05-02
FI87140C (fi) 1992-12-10
UA11075A (uk) 1996-12-25
LV10051B (en) 1995-06-20
ATE55250T1 (de) 1990-08-15
ES2017982B3 (es) 1991-03-16
HUT44932A (en) 1988-05-30
JPS63159319A (ja) 1988-07-02
CA1314231C (en) 1993-03-09
DD262582A5 (de) 1988-12-07
LV10051A (lv) 1994-05-10
RU1836079C (ru) 1993-08-23
EG18333A (en) 1993-12-30
IN168119B (es) 1991-02-09
DK569687D0 (da) 1987-10-30
FI874727A (fi) 1988-05-01
DK569687A (da) 1988-05-01
IL84312A0 (en) 1988-03-31
PT86032B (pt) 1990-08-31
HU197987B (en) 1989-07-28
KR880004814A (ko) 1988-06-27
NO873860D0 (no) 1987-09-15
PT86032A (de) 1987-11-01
AU8052987A (en) 1988-05-05

Similar Documents

Publication Publication Date Title
ES2040394T3 (es) Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
ES2036221T3 (es) Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.
MX8958A (es) Procedimiento para obtener un preparado liofilizado que contiene ifosfamida.
GR3004440T3 (es)
IT8547683A0 (it) Procedimento per la preparazione dicomposti 1,3-diossolan-4-metanolici otticamente attivi
AU8240387A (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
DK23490A (da) Implanteret antibiotisk tilberedning med reguleret frigivelse
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
ES2064652T3 (es) Derivados de naftaleno- y tetrahidronaftaleno-gem-difosfonato.
ATA279787A (de) Verwendung eines oestradiolderivates zur herstellung eines pharmazeutischen praeparates zur unterdrueckung der immunreaktion
ATE75613T1 (de) 17-benzylspartein-derivate enthaltende positiv inotrop wirksame pharmazeutische zubereitungen.
ES541805A0 (es) Un procedimiento para la preparacion de un derivado de 1,4: 3,6-dianhidrohexitol
ES541806A0 (es) Un procedimiento para la preparacion de un derivado de 1,4: 3,6-dianhidrohexitol
ES541807A0 (es) Un procedimiento para la preparacion de un derivado de 1,4: 3,6-dianhidrohexitol
IT8842522A0 (it) Procedimento per la preparazione di 2 - (2,4 diclorofenil)metil4 - (1,1, 3,3 tetrametilbutil)fenolo (clofoctolo)
ES557020A0 (es) Un procedimiento para la preparacion de derivados de aminofenol